GDF15 and heart failure: In this current analysis of the Empagliflozin in Heart Failure Patients with Reduced Ejection Fraction (Empire HF) trial [26], we sought to evaluate the effect of empagliflozin on plasma GDF-15 along with the inflammatory marker high sensitive C-reactive protein (hsCRP), and marker of myocardial injury high sensitive troponin T (hsTNT) in patients with HFrEF.